2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 752

Cardiovascular Outcomes Are Worse In Microscopic Polyangiitis Compared To Granulomatosis With Polyangiitis: Data From An Inception Cohort Of Patients With Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis
Abstract Number: 1671

Cardiovascular Risk At Incidence Of Giant Cell Arteritis: A Population Based Retrospective Cohort Study
Abstract Number: 286

Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis
Abstract Number: 372

Cardiovascular Risk In Intensively Treated Rheumatoid Arthritis: Comparison To An Osteoarthritis Population. First Prospective Analysis Of The ACT-CVD Cohort
Abstract Number: 1975

Cardiovascular Risk Stratification In Rheumatic Diseases : Carotid Ultrasound Is More Sensitive Than Coronary Artery Calcification Score To Detect Subclinical atherosclerosis In Patients With Rheumatoid Arthritis
Abstract Number: 440

Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
Abstract Number: 384

Carotid Artery Plaques Are Associated With Coronary Atherosclerosis In Patients With Inflammatory Joint Diseases Independent Of Several Cardiovascular Risk Calculators
Abstract Number: 2763

Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis
Abstract Number: 50

Cartilage Matrix Remodeling and Activation Of Canonical Wnt- Signaling Precedes Calcification and OA-Like Changes In Mice
Abstract Number: 156

Cartilage Peptide Profiling: Identifying Novel OA Biomarkers For Early Disease Detection
Abstract Number: 85

Cartilaginous Uric Acid Deposition In Advanced Osteoarthritis: Innocent Bystander Or Promotor Of Cartilage Destruction?
Abstract Number: 2744

Caspase 8 Modulates The Polarisome To Prevent Lung Fibrosis In a Murine Ssc-Like Disease Model
Abstract Number: 11

Catastrophic Antiphospholipid Syndrome (CAPS): Clinical, Immunologic Features, and Outcome Of 441 Patients From The “CAPS Registry”
Abstract Number: 1320

Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics
Abstract Number: 614

Causes Of Mortality In Lupus Patients Followed Prospectively At a Large Single-Centre Lupus Clinic

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].